Passive methods for anti-microbial biological meshes
View Patent ↗Tissue matrices having anti-microbial properties are provided. In certain embodiments, the tissue matrices include cationic anti-microbial agents that form a stable bond with the tissue matrices without adversely affecting the biologic properties of the tissue matrices.
1. A modified tissue matrix prepared by a process comprising:
selecting an acellular dermal matrix; and
contacting the acellular dermal matrix with a solution consisting essentially of an aqueous buffer and chlorhexidine,
wherein the chlorhexidine stably binds to the acellular dermal matrix by passive adsorption, and wherein the aqueous buffer is non-denaturing.
2. The modified tissue matrix of claim 1 , wherein the chlorhexidine is present in the aqueous solution at a concentration ranging from about 0.002% to about 0.2% weight/volume (w/v).
3. The modified tissue matrix of claim 1 , wherein the chlorhexidine is present in the aqueous solution at a concentration ranging from about 0.043% to about 0.096% w/v.
4. The modified tissue matrix of claim 1 , wherein the acellular dermal matrix is not cross-linked or denatured during binding of the chlorhexidine, and the chlorhexidine is not covalently modified by binding to the acellular dermal matrix.
5. The modified tissue matrix of claim 1 , wherein the modified tissue matrix retains anti-microbial properties in an aqueous environment for at least two weeks after binding of the one or more cationic anti-microbial agents.
6. The modified tissue matrix of claim 1 , wherein the one or more chlorhexidine remains bound to the modified tissue matrix when the modified tissue matrix is placed in a non-denaturing aqueous solution.
7. The modified tissue matrix of claim 1 , wherein the bound chlorhexidine retains greater than 75% of its activity when the modified tissue matrix is placed in PBS for two weeks at room temperature.
8. The modified tissue matrix of claim 1 , wherein the acellular dermal matrix has been exposed to E-beam radiation.
9. A modified tissue matrix comprising:
an acellular dermal matrix; and
at least one cationic anti-microbial agent that has been stably bound to the acellular dermal matrix by passive adsorption,
wherein the at least one cationic anti-microbial agent is consists essentially of chlorhexidine.
10. The modified tissue matrix of claim 9 , wherein the chlorhexidine has been applied to the acellular dermal matrix in an aqueous solution at a concentration ranging from about 0.002% to about 0.2% weight/volume (w/v).
11. The modified tissue matrix of claim 9 , wherein the chlorhexidine has been applied to the acellular dermal matrix in an aqueous solution at a concentration ranging from about 0.043% to about 0.096% w/v.
12. The modified tissue matrix of claim 9 , wherein the acellular dermal matrix is not cross-linked or denatured, and the chlorhexidine is not covalently modified by binding to the acellular dermal matrix.
13. The modified tissue matrix of claim 9 , wherein the modified tissue matrix retains anti-microbial properties in an aqueous environment for at least two weeks after binding of the chlorhexidine.
14. The modified tissue matrix of claim 9 , wherein the chlorhexidine remains bound to the modified tissue matrix when the modified tissue matrix is placed in a non-denaturing aqueous solution.
15. The modified tissue matrix of claim 9 , wherein the chlorhexidine retains greater than 75% of its activity when the modified tissue matrix is placed in PBS for two weeks at room temperature.
16. The modified tissue matrix of claim 9 , wherein the acellular dermal matrix has been exposed to E-beam radiation.